Psychosocial barriers to follow-up adherence after an abnormal cervical cytology test result among low-income, inner-city women

Journal of Primary Care and Community Health

Volumn 5, Issue 4, 2014, Pages 234-241

  Hui, Siu Kuen Azor ^a   Miller, Suzanne M ^a   Wen, Kuang Yi ^a   Fang, Zhu ^b   Li, Tianyu ^a   Buzaglo, Joanne ^c   Hernandez, Enrique ^d  

^a TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

^b Everest Clinical Research   (United States)

^c Cancer Support Community (CSC) Research and Training Institute   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Cervical risk; Low income women; Psychosocial barriers

Indexed keywords

ADULT; ATTITUDE TO HEALTH; COLPOSCOPY; COPING BEHAVIOR; COUNSELING; CROSS-SECTIONAL STUDY; ETIOLOGY; FEMALE; HUMAN; INCOME; MENTAL STRESS; PAPANICOLAOU TEST; PATIENT COMPLIANCE; PENNSYLVANIA; PSYCHOLOGY; SOCIOECONOMICS; URBAN POPULATION; UTERINE CERVIX TUMOR; VAGINA SMEAR; YOUNG ADULT;

ADAPTATION, PSYCHOLOGICAL; ADULT; COLPOSCOPY; COUNSELING; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INCOME; PAPANICOLAOU TEST; PATIENT COMPLIANCE; PENNSYLVANIA; SOCIOECONOMIC FACTORS; STRESS, PSYCHOLOGICAL; URBAN POPULATION; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84930008942     PISSN: 21501319     EISSN: 21501327     Source Type: Journal    
DOI: 10.1177/2150131914529307     Document Type: Article

References (51)

1. American Cancer Society. Cancer Facts & Figures 2013. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/ documents/document/acspc-036845.pdf. Accessed March 10, 2014.
2. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297:813-819.
3. Hariri S, Unger ER, Sternberg M, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003-2006. J Infect Dis. 2011;204:566-573.
4. Kahn JA, Lan D, Kahn RS. Sociodemographic factors associated with high-risk human papillomavirus infection. Obstet Gynecol. 2007;110:87-95.
5. Dunne EF, Sternberg M, Markowitz LE, et al. Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States-National Health and Nutrition Examination Survey, 2003-2006: opportunity to measure HPV vaccine impact? J Infect Dis. 2011;204:562-565.
6. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis. 2013;208:385-393.
7. Laz TH, Rahman M, Berenson AB. An update on human papillomavirus vaccine uptake among 11-17-year-old girls in the United States: National Health Interview Survey, 2010. Vaccine. 2012;30:3534-3540.
8. Forhan SE, Gottlieb SL, Sternberg MR, et al. Prevalence of sexually transmitted infections among female adolescents aged 14 to 19 in the United States. Pediatrics. 2009;124: 1505-1512.
9. Miller SM, Roussi P. Cervical cancer screening. In: Holland JC, Breitbart WS, Jacobsen PB, Lederberg MS, Loscalzo MJ, McCorkle R, eds. Psycho-oncology. 2nd ed. New York, NY: Oxford University Press; 2010:84-89.
10. National Cancer Institute. Fact Sheet 5.16, Pap Test. 2010; http://www.cancer.gov/cancertopics/factsheet/detection/ Fs5_16.pdf. Accessed April 27, 2012.
11. Tiltman AJ. The pathology of cervical tumours. Best Pract Res Clin Obstet Gynaecol. 2005;19:485-500.
12. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 Consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis. 2007;11: 223-239.
13. Massad LS, Einstein MH, Huh WK, et al. 2012 Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121:829-846.
14. Benard VB, Lawson HW, Eheman CR, Anderson C, Helsel W. Adherence to guidelines for follow-up of low-grade cytologic abnormalities among medically underserved women. Obstet Gynecol. 2005;105:1323-1328.
15. Doyle JP, Parker RM, Jacobson TA, McNagny SE. Breast and cervical cancer screening in an inner-city medical walkin clinic: taking advantage of an often missed opportunity. Am J Prev Med. 1996;12:345-350.
16. Engelstad LP, Stewart SL, Nguyen BH, et al. Abnormal Pap smear follow-up in a high-risk population. Cancer Epidemiol Biomarkers Prev. 2001;10:1015-1020.
17. Jones BA, Novis DA. Follow-up of abnormal gynecologic cytology: a College of American Pathologists Q-Probes study of 16 132 cases from 306 laboratories. Arch Pathol Lab Med. 2000;124:665-671.
18. Marcus AC, Crane LA, Kaplan CP, et al. Improving adherence to screening follow-up among women with abnormal Pap smears: results from a large clinic-based trial of three intervention strategies. Med Care. 1992;30:216-230.
19. Miller SM, Siejak KK, Schroeder CM, Lerman C, Hernandez E, Helm CW. Enhancing adherence following abnormal Pap smears among low-income minority women: a preventive telephone counseling strategy. J Natl Cancer Inst. 1997;89:703-708.
20. Engelstad LP, Stewart S, Otero-Sabogal R, Leung MS, Davis PI, Pasick RJ. The effectiveness of a community outreach intervention to improve follow-up among underserved women at highest risk for cervical cancer. Prev Med. 2005;41: 741-748.
21. Fox P, Arnsberger P, Zhang X. An examination of differential follow-up rates in cervical cancer screening. J Community Health. 1997;22:199-209.
22. Hartz LE, Fenaughty AM. Management choice and adherence to follow-up after colposcopy in women with cervical intraepithelial neoplasia 1. Obstet Gynecol. 2001;98:674-679.
23. Kaplan CP, Bastani R, Belin TR, Marcus A, Nasseri K, Hu MY. Improving follow-up after an abnormal pap smear: results from a quasi-experimental intervention study. J Womens Health Gend Based Med. 2000;9:779-790.
24. McKee MD, Schechter C, Burton W, Mulvihill M. Predictors of follow-up of atypical and ASCUS papanicolaou tests in a high-risk population. J Fam Pract. 2001;50:609.
25. Abercrombie PD. Improving adherence to abnormal Pap smear follow-up. J Obstet Gynecol Neonatal Nurs. 2001;30:80-88.
26. Jean-Pierre P, Hendren S, Fiscella K, et al. Understanding the processes of patient navigation to reduce disparities in cancer care: perspectives of trained navigators from the field. J Cancer Educ. 2011;26:111-120.
27. Crane LA. Social support and adherence behavior among women with abnormal Pap smears. J Cancer Educ. 1996;11:164-173.
28. Eger RR, Peipert JF. Risk factors for noncompliance in a colposcopy clinic. J Reprod Med. 1996;41:671-674.
29. Eggleston KS, Coker AL, Das IP, Cordray ST, Luchok KJ. Understanding barriers for adherence to follow-up care for abnormal pap tests. J Womens Health (Larchmt). 2007;16:311-330.
30. Lerman C, Hanjani P, Caputo C, et al. Telephone counseling improves adherence to colposcopy among lower-income minority women. J Clin Oncol. 1992;10:330-333.
31. Marcus AC, Kaplan CP, Crane LA, et al. Reducing lossto- follow-up among women with abnormal Pap smears. Results from a randomized trial testing an intensive follow- up protocol and economic incentives. Med Care. 1998;36:397-410.
32. Nelson K, Geiger AM, Mangione CM. Effect of health beliefs on delays in care for abnormal cervical cytology in a multiethnic population. J Gen Intern Med. 2002;17:709-716.
33. McKee MD, Lurio J, Marantz P, Burton W, Mulvihill M. Barriers to follow-up of abnormal Papanicolaou smears in an urban community health center. Arch Fam Med. 1999;8:129-134.
34. Tejeda S, Darnell JS, Cho YI, Stolley MR, Markossian TW, Calhoun EA. Patient barriers to follow-up care for breast and cervical cancer abnormalities. J Womens Health (Larchmt). 2013;22:507-517.
35. Miller SM, Shoda Y, Hurley K. Applying cognitive-social theory to health-protective behavior: breast self-examination in cancer screening. Psychol Bull. 1996;119:70-94.
36. Miller SM, Mischel W, O'Leary A, Mills M. From human papillomavirus (HPV) to cervical cancer: psychological processes in infection, detection, and control. Ann Behav Med. 1996;18:219-228.
37. Miller SM, Rodoletz M, Buzaglo J, Gray T, Sherman K. Monitoring attentional style among low-income minority women at risk for cervical cancer: cognitive social determinants of adjustment and ddherence. Poster presented at: 12th Annual Meeting of the Society of Behavioral Medicine; 2001.
38. Miller SM, Hui SA, Wen KY, et al. Tailored telephone counseling to improve adherence to follow-up regiments after an abnormal Pap smear among minority, underserved women. Patient Educ Couns. 2013;93:488-495.
39. Ell K, Vourlekis B, Muderspach L, et al. Abnormal cervical screen follow-up among low-income Latinas: Project SAFe. J Womens Health Gend Based Med. 2002;11:639-651.
40. Carey P, Gjerdingen DK. Follow-up of abnormal Papanicolaou smears among women of different races. J Fam Pract. 1993;37:583-587.
41. National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Stat Fact Sheets: Cervix Uteri. 2013. http://seer.cancer.gov/statfacts/html/cervix.html. Accessed June 14, 2013.
42. Institute of Medicine. Speaking of health: assessing health communication strategies for diverse populations. 2002. http://www.nap.edu/catalog.php?record_id=10018. Accessed June 12, 2013.
43. National Cancer Institute. Making Health Communication Programs Work. 2002. http://www.cancer.gov/cancertopics/ cancerlibrary/pinkbook. Accessed March 10, 2014.
44. Battaglia TA, Bak SM, Heeren T, et al. Boston Patient Navigation Research Program: the impact of navigation on time to diagnostic resolution after abnormal cancer screening. Cancer Epidemiol Biomarkers Prev. 2012;21:1645-1654.
45. Freund KM, Battaglia TA, Calhoun E, et al. National Cancer Institute Patient Navigation Research Program: methods, protocol, and measures. Cancer. 2008;113:3391-3399.
46. Markossian TW, Darnell JS, Calhoun EA. Follow-up and timeliness after an abnormal cancer screening among underserved, urban women in a patient navigation program. Cancer Epidemiol Biomarkers Prev. 2012;21:1691-1700.
47. Paskett ED, Harrop JP, Wells KJ. Patient navigation: an update on the state of the science. CA Cancer J Clin. 2011;61:237- 249.
48. Paskett ED, Katz ML, Post DM, et al. The Ohio Patient Navigation Research Program: does the American Cancer Society patient navigation model improve time to resolution in patients with abnormal screening tests? Cancer Epidemiol Biomarkers Prev. 2012;21:1620-1628.
49. Wells KJ, Battaglia TA, Dudley DJ, et al. Patient navigation: state of the art or is it science? Cancer. 2008;113:1999-2010.
50. Yabroff KR, Kerner JF, Mandelblatt JS. Effectiveness of interventions to improve follow-up after abnormal cervical cancer screening. Prev Med. 2000;31:429-439.
51. Radecki Breitkopf C, Dawson L, Grady JJ, Breitkopf DM, Nelson-Becker C, Snyder RR. Intervention to improve follow- up for abnormal Papanicolaou tests: a randomized clinical trial [published online June 3, 2013]. Health Psychol. doi:10.1037/a0032722.